Institute of Oncology Ljubljana Leverages SOPHiA DDM™ Platform for Cancer Research
SOPHiA DDM™ deep-learning algorithm will help determine HRD status of tumors for Institute of Oncology Ljubljana researchers
BOSTON and LAUSANNE, Switzerland — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the Institute of Oncology Ljubljana (IOL), a comprehensive public institution for detection, treatment and research of cancer, based in Ljubljana, Slovenia, is live on SOPHiA DDM™. To help advance its clinical oncology research, IOL is leveraging low-pass Whole Genome Sequencing (WGS) data computed by the proprietary GIInger deep-learning algorithm from SOPHiA GENETICS to increase research efficiency and obtain actionable clinical insights to make data-driven decisions that improve the quality of patient care.
IOL will use SOPHiA DDM™ to identify Homologous Recombination Deficiency (HRD) in tumor samples. HRD is when a cell is unable to repair double-stranded breaks, which can lead to the accumulation of genomic scars. HRD is a common feature of high-grade serous ovarian cancer (HGSOC) as well as breast, prostate, and pancreatic cancers, and can be used as a potential predictive biomarker for therapy response.
“As the leading institution in the country for the detection, treatment and research of cancer, we work to ensure balanced and proper development of oncology health services. This is why research and education hold a special position at the Institute,” said Dr. Srdjan Novaković, DSc (Biol.), Head of the Department of Molecular Diagnostic, Institute of Oncology Ljubljana. “With the support of SOPHiA GENETICS, our researchers will be able to expedite testing and analysis associated with the determination of HRD, helping to facilitate faster clinical decision-making and advance cancer research in Slovenia.”
IOL will use the SOPHiA DDM™ Platform, which offers an application that is capable of combining information from germline and somatic homologous recombination repair (HRR) mutations, including BRCA1 and BRCA2, with a measure of genomic scarring. Through this approach, users can obtain reliable and fast, in-house data. HRR is a cellular process that repairs double-stranded breaks (DSB) arising from the DNA replication process or resulting from exposure to DNA-damaging agents.
“Our work at SOPHiA GENETICS is to democratize data-driven medicine,” said Esteban Czwan, Managing Director, EMEA, SOPHiA GENETICS. “The SOPHiA DDM™ Platform will support the Institute of Oncology Ljubljana to gain comprehensive genomic insights powered by deep learning algorithms, leading to data-driven conclusions, while helping them increase efficiency and volume of profiles analyzed.”
With the cloud-based SOPHiA DDM™ Platform, the Institute of Oncology Ljubljana will amass an in-house database that will help to further their cancer research and progress for all of Slovenia.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution is available as a CE-IVD product for In Vitro Diagnostic Use in Europe, Turkey, and Slovenia. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.